COMMUNIQUÉS West-GlobeNewswire
-
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
25/02/2026 -
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
25/02/2026 -
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
25/02/2026 -
Novonesis delivered strong organic sales growth of 7% in 2025
25/02/2026 -
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
25/02/2026 -
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026 -
Novonesis' Annual Report 2025
25/02/2026 -
Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
25/02/2026 -
Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026
25/02/2026 -
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
25/02/2026 -
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
25/02/2026 -
Capital Increase in Genmab as a Result of Employee Warrant Exercise
24/02/2026 -
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
24/02/2026 -
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
24/02/2026 -
Cannabix Technologies Closes Non-Brokered Private Placement
24/02/2026 -
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
24/02/2026 -
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
24/02/2026 -
Palvella Therapeutics Announces Proposed Public Offering
24/02/2026 -
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
24/02/2026
Pages